Clinical Trial Update: Triheptanoin Treatment Trial for Patients With Long-chain Fatty Acid Beta-oxidation Defects [Phase 3]

View source ↗

Summary

A Phase 3 trial of Triheptanoin for long-chain fatty acid oxidation disorders has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long-chain Fatty Acid Oxidation Disorders

Drugs mentioned

• DOJOLVI (triheptanoin)

Snippet

Sponsor: Maria Luz Couce Pico | Conditions: Long-chain Fatty Acid Transport Deficiency | Phase 3 | Status: WITHDRAWN